Tirzepatide is a dual GLP-1/GIP receptor agonist — often called a “twincretin” — that has rapidly become one of the most talked-about molecules in metabolic peptide research. By activating both incretin pathways simultaneously, tirzepatide promotes satiety, slows gastric emptying, enhances insulin signalling, and appears to independently influence adipose tissue metabolism, producing effects on body weight and glucose handling that have consistently outperformed single-receptor approaches in published studies. Its extended half-life allows for once-weekly research protocols, and ongoing investigation spans cardiometabolic health, hepatic fat metabolism, and sleep-disordered breathing. Tirzepatide has set a new benchmark in incretin-based research and remains a central reference compound for anyone studying metabolic regulation and body composition.
Tirzepatide 30mg
£135.00
About Tirzepatide 30mg
Tirzepatide is a synthetic 39-amino acid peptide engineered as a dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Its structure incorporates a C20 fatty diacid moiety that enables binding to serum albumin, extending its pharmacokinetic half-life and allowing for once-weekly administration in research protocols. This dual-receptor design — sometimes referred to as a “twincretin” — reflects a growing recognition that targeting multiple incretin pathways simultaneously may produce metabolic effects that exceed what either pathway achieves alone.
The twincretin concept challenges an earlier view that GIP signalling might be counterproductive in the context of metabolic dysfunction. Tirzepatide’s design deliberately exploits both incretin axes: GLP-1 receptor activation promotes satiety, slows gastric emptying, and enhances glucose-dependent insulin secretion, while GIP receptor engagement appears to amplify insulin responses and may contribute independently to adipose tissue metabolism. The result is a compound that has generated some of the most striking efficacy data in modern metabolic peptide research, positioning tirzepatide as a central reference molecule for investigators working across obesity, diabetes, and cardiometabolic science.
Research Summary
The clinical evidence base for tirzepatide in type 2 diabetes (T2D) research was established through the SURPASS programme — a series of large-scale Phase 3 trials comparing tirzepatide against placebo and active comparators. Across these studies, tirzepatide demonstrated substantial reductions in HbA1c and body weight in T2D models. Notably, SURPASS-2 compared tirzepatide directly against semaglutide 1 mg, a well-established GLP-1 receptor agonist. At all doses tested, tirzepatide achieved greater reductions in both HbA1c and body weight than semaglutide, providing some of the first head-to-head clinical data suggesting that dual incretin agonism may offer advantages over GLP-1 targeting alone.
The SURMOUNT trial programme extended tirzepatide research into the obesity setting, enrolling participants without T2D. SURMOUNT-1, published in the New England Journal of Medicine, reported mean weight reductions of up to approximately 22.5% at the highest dose over 72 weeks — results that set a new benchmark for pharmacological weight reduction in clinical research. These data catalysed widespread interest in tirzepatide as a research tool for studying the biological underpinnings of weight regulation and the potential for incretin-based interventions to reshape body composition.
The role of GIP receptor agonism within tirzepatide’s mechanism has been a subject of active scientific debate. Some researchers have proposed that GIP contributes primarily through potentiation of insulin secretion and direct effects on adipocyte biology, including enhanced lipid storage capacity in subcutaneous fat depots. Others point to emerging data suggesting GIP may modulate central appetite circuits independently of GLP-1. Disentangling the relative contributions of each receptor pathway remains an important area of investigation, with tirzepatide serving as a key pharmacological probe.
Cardiovascular outcomes research represents an expanding frontier for tirzepatide. The SURPASS-CVOT trial is evaluating major adverse cardiovascular events in at-risk populations, driven by the recognition that metabolic interventions capable of reducing weight and improving glycaemic control may also influence cardiovascular risk trajectories. Preliminary signals from earlier SURPASS data — including improvements in blood pressure, lipid profiles, and inflammatory markers — have provided mechanistic rationale for these dedicated cardiovascular studies.
Research into tirzepatide’s effects on obstructive sleep apnoea has also gained momentum. The SURMOUNT-OSA studies examined the compound’s impact on apnoea-hypopnoea index scores, with results suggesting meaningful reductions in sleep-disordered breathing events alongside weight loss. These findings have opened a new line of inquiry into the relationship between incretin signalling, body composition changes, and respiratory physiology during sleep.
Another rapidly developing research area involves metabolic-associated steatohepatitis (MASH), formerly known as NASH. Given tirzepatide’s demonstrated effects on body weight, insulin sensitivity, and hepatic fat content observed in earlier metabolic trials, dedicated studies are now investigating its potential to influence liver histology. Early-phase data have been encouraging, and this line of research positions tirzepatide at the intersection of endocrinology and hepatology — a convergence that reflects the increasingly integrated approach to metabolic disease investigation.
There are no reviews yet.